Payment overview · 2025
General Payments
$897.15
52 reported records · 15 companies
Healthcare provider profile · identity verified
Joseph J Depetro, MD
Allopathic & Osteopathic Physicians|Family Medicine · WELLSBURG, WV · NPI 1083764666
Verified facts
What the public records show
CMS Open Payments records show Joseph J Depetro, MD received $897.15 in general payments during 2025 across 52 reported records.
ABBVIE INC. accounted for 17.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Mounjaro by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 328 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $158.68 | 17.7% | 12 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $101.12 | 11.3% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $91.99 | 10.2% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $75.92 | 8.5% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $66.96 | 7.5% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $52.04 | 5.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.54 | 5.7% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $51.51 | 5.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.41 | 5.7% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $51.35 | 5.7% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $42.40 | 4.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.38 | 3.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.18 | 3.6% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.39 | 2.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.28 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $897.15 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $140.05 | 11 | 2025 |
Source payment records
|
|||||
| BRILINTA Normalized: brilinta |
Drug | AstraZeneca Pharmaceuticals LP | $91.99 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $79.91 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $75.92 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $66.96 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $52.04 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $51.51 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $51.41 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $51.41 | 3 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $51.35 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $42.40 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.38 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $34.38 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.18 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.21 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 328 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 97 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
97 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
328 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 737 | 164 |
| Levothyroxine Sodium | Levothyroxine Sodium | 696 | 125 |
| Pantoprazole Sodium | Pantoprazole Sodium | 539 | 113 |
| Losartan Potassium | Losartan Potassium | 423 | 84 |
| Lisinopril | Lisinopril | 329 | 75 |
| Eliquis | Apixaban | 328 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 327 | 78 |
| Potassium Chloride | Potassium Chloride | 287 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 262 | 64 |
| Pravastatin Sodium | Pravastatin Sodium | 261 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 250 | 45 |
| Omeprazole | Omeprazole | 210 | 71 |
| Donepezil Hcl | Donepezil Hcl | 198 | 23 |
| Furosemide | Furosemide | 186 | 42 |
| Metformin Hcl | Metformin Hcl | 181 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 179 | 41 |
| Glimepiride | Glimepiride | 172 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 171 | 37 |
| Metformin Hcl Er | Metformin Hcl | 166 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 163 | 43 |
| Alprazolam | Alprazolam | 151 | 48 |
| Gabapentin | Gabapentin | 141 | 29 |
| Trazodone Hcl | Trazodone Hcl | 132 | 16 |
| Allopurinol | Allopurinol | 127 | 37 |
| Spironolactone | Spironolactone | 121 | 19 |
| Atenolol | Atenolol | 120 | 25 |
| Finasteride | Finasteride | 111 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 110 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 20 |
| Buspirone Hcl | Buspirone Hcl | 101 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 101 | 23 |
| Simvastatin | Simvastatin | 101 | 32 |
| Sertraline Hcl | Sertraline Hcl | 100 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 98 | 29 |
| Ozempic | Semaglutide | 97 | 18 |
| Carvedilol | Carvedilol | 89 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 24 |
| Doxazosin Mesylate | Doxazosin Mesylate | 84 | 22 |
| Memantine Hcl | Memantine Hcl | 84 | 13 |
| Montelukast Sodium | Montelukast Sodium | 84 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 83 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 24 |
| Lovastatin | Lovastatin | 77 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 71 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 21 |
| Famotidine | Famotidine | 69 | 16 |
| Tramadol Hcl | Tramadol Hcl | 68 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 65 | 12 |
| Warfarin Sodium | Warfarin Sodium | 61 | 14 |
| Januvia | Sitagliptin Phosphate | 60 | 13 |
| Meloxicam | Meloxicam | 59 | 21 |
| Memantine Hcl Er | Memantine Hcl | 59 | suppressed |
| Ezetimibe | Ezetimibe | 58 | 17 |
| Xarelto | Rivaroxaban | 58 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 56 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 54 | 17 |
| Clonazepam | Clonazepam | 53 | suppressed |
| Primidone | Primidone | 53 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 52 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 19 |
| Celecoxib | Celecoxib | 46 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 45 | suppressed |
| Azithromycin | Azithromycin | 43 | 33 |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 30 |
| Synthroid | Levothyroxine Sodium | 38 | 13 |
| Meclizine Hcl | Meclizine Hcl | 37 | 16 |
| Tradjenta | Linagliptin | 36 | suppressed |
| Rexulti | Brexpiprazole | 35 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 18 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 20 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Piroxicam | Piroxicam | 15 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | 13 |
| Acetylcysteine | Acetylcysteine | 13 | suppressed |
| Calcium Acetate | Calcium Acetate | 13 | suppressed |
| Leflunomide | Leflunomide | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 13 |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Diclofenac Sodium Er | Diclofenac Sodium | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $897.15 · 52 records | ABBVIE INC. | BRILINTA, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, EVENITY, GARDASIL 9, JARDIANCE, Kerendia, Korlym, NURTEC ODT, Ozempic, QULIPTA, REXULTI, The Cologuard Plus Collection Kit, UBRELVY, UNITHROID, VAXNEUVANCE, VRAYLAR, Veozah, YUPELRI | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error